LCN2 and breast carcinoma: Furthermore, local and systemic levels of CHI3L1 and LCN2, two immune-related biomarkers used for prognosticating and monitoring disease in breast cancer patients and mice [6, 12–14], provided an additional verification of the tumor progression in 4T1 inoculated mice with and without RAW264.7 macrophages.